Skip to main navigation Skip to main content Skip to footer For Medicare For Providers For Brokers For Employers Español For Individuals & Families: For Individuals & Families Medical Dental Other Supplemental Explore coverage through work How to Buy Health Insurance Types of Dental Insurance Open Enrollment vs. Special Enrollment See all topics Shop for Medicare plans Member Guide Find a Doctor Log in to myCigna
Home Knowledge Center Wellness Library ravulizumab

ravulizumab

Pronunciation: RAV ue LIZ ue mab

Brand: Ultomiris

What is the most important information I should know about ravulizumab?

What is the most important information I should know about ravulizumab?

You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, flu-like symptoms, muscle pain, headache, confusion, neck or back stiffness, vomiting, rash, or your eyes are more sensitive to light.

You will need to receive certain vaccinations before you start using ravulizumab.

Read the Patient Safety Card about serious infections and the symptoms to watch for. Keep this card with you at all times while using ravulizumab and for at least 8 months after your last dose.

What is ravulizumab?

What is ravulizumab?

Ravulizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults and children at least 1 month old.

Ravulizumab is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children at least 1 month old. This medicine is not for use in treating HUS that is related to Shiga toxin E. coli.

Ravulizumab is available only under a special program. You must be registered in the program and understand the risks and benefits of this medicine.

Ravulizumab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving ravulizumab?

What should I discuss with my healthcare provider before receiving ravulizumab?

You should not be treated with ravulizumab if you are allergic to it, if you have a meningococcal infection (such as meningitis or sepsis), or if you are not currently vaccinated against meningitis (unless the risks of delaying treatment outweigh the risks of developing meningitis).

You will need to receive a vaccine to protect against meningococcal infections at least 2 weeks before you start using ravulizumab. If your child is treated with ravulizumab, make sure he or she is vaccinated against pneumonia and influenza type B (Hib).

If you need to start receiving this medicine before you are vaccinated, you may be given antibiotic medicine to take during the first 2 weeks of ravulizumab treatment.

Tell your doctor if you have recently had any symptoms of infection (fever, chills, or flu-like symptoms).

Tell your doctor if you are pregnant. It is not known whether ravulizumab will harm an unborn baby. However, having PNH during pregnancy may cause complications in the baby or the mother, including blood clots, infections, bleeding, miscarriage, premature delivery, or death. The benefit of treating PNH may outweigh any risks to the baby or the mother.

Do not breastfeed while using ravulizumab, and for at least 8 months after your last dose.

Not approved for use by anyone younger than 1 month old.

How is ravulizumab given?

How is ravulizumab given?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

If you've been using another drug called eculizumab (Soliris), you will need to wait 2 weeks after your last dose of eculizumab before starting treatment with ravulizumab.

Ravulizumab is injected into a vein by a healthcare provider. The first two infusions are usually given 2 weeks apart, followed by an infusion once every 4-8 weeks.

After each infusion, you will be watched closely for at least 1 hour to make sure you do not have an allergic reaction.

Doses are based on weight. Your dose may change if you gain or lose weight.

You may get infections more easily, even serious or fatal infections. You will need frequent medical tests.

Read the Patient Safety Card about serious infections and the symptoms to watch for. Keep this card with you at all times while using ravulizumab and for at least 8 months after your last dose. Your infection risk could last for several months after you stop using ravulizumab.

Some people may have an increased risk of gonorrhea (a sexually transmitted disease). Talk with your doctor about safe ways to keep from getting an infection during sex.

Ravulizumab can have long lasting effects on your body, even after you stop using this medicine. If you have PNH and you stop using ravulizumab, your doctor may need to check your progress for at least 16 weeks after your last dose. If you have aHUS and you stop using ravulizumab, your doctor may need to check you for at least 12 months after your last dose.

What happens if I miss a dose?

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your ravulizumab injection.

What happens if I overdose?

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving ravulizumab?

What should I avoid while receiving ravulizumab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of ravulizumab?

What are the possible side effects of ravulizumab?

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel light-headed or if you have chest pain, trouble breathing, or swelling in your face.

Call your doctor right away if you have signs of infection such as:

  • muscle pain with flu-like symptoms;
  • fever and a rash;
  • fever and a headache;
  • headache and stiffness in your neck or back;
  • headache and nausea or vomiting;
  • confusion; or
  • your eyes may be more sensitive to light.

Call your doctor at once if you have symptoms of gonorrhea, such as:

  • pain or burning when you urinate;
  • pain or swelling of the genital or rectal area;
  • unusual vaginal bleeding; or
  • foul discharge from the penis or vagina.

If you stop using ravulizumab, tell your doctor if you have any new or worsening symptoms, such as: tiredness, confusion, stomach pain, chest pain, trouble breathing or swallowing, (in men) trouble having an erection, blood in your urine, a seizure, or loss of consciousness.

Common side effects may include:

  • fever;
  • high blood pressure;
  • diarrhea, nausea, vomiting;
  • headache; or
  • cold symptoms such as stuffy nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect ravulizumab?

What other drugs will affect ravulizumab?

Other drugs may affect ravulizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Where can I get more information?

Your pharmacist can provide more information about ravulizumab.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna

Audiences

Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

Cigna Company Information

About Cigna Company Profile Careers Newsroom Investors Suppliers Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Non-Discrimination Notice [PDF] Language Assistance [PDF] Report Fraud Sitemap

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., and Cigna HealthCare of North Carolina, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities  that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details